Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

This study is using blood-based tests (liquid biopsy) and molecular analysis to predict which patients with limited-stage small cell lung cancer will respond to a type of immunotherapy (PD-L1 inhibitor) after completing chemotherapy and radiation treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with limited-stage small cell lung cancer (cancer confined to one side of the chest) - You have had no more than 2 cycles of chemotherapy, or no prior treatment at all - You are in good health (ECOG performance status 0 or 1) - Your blood counts, kidney, and liver function are within acceptable ranges - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - Your small cell lung cancer has spread to the other side of the chest or to distant organs - You have previously received extensive cancer treatment - Your organ function is too impaired to tolerate treatment Talk to your doctor to see if this trial is right for you.